Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm plus ) advanced NSCLC: Updated data from the GioTag real-world study

被引：0
|
作者：
Hochmair, M. J. [1 ,2 ]
Morabito, A. [3 ]
Hao, D. [4 ]
Yang, C-T. [5 ]
Soo, R. [6 ]
Yang, J. C-H. [7 ]
Gucalp, R. [8 ]
Halmos, B. [8 ]
Wang, L. [9 ]
Golembesky, A. [10 ]
Maerten, A. [10 ]
Cufer, T. [11 ]
机构：
[1] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria
[2] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria
[3] Fdn G Pascale IRCCS, Ist Nazl Tumori, Thorac Med Oncol, Naples, Italy
[4] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[5] Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan
[6] Natl Univ Singapore Hosp, Dept Haematol Oncol, Singapore, Singapore
[7] Natl Taiwan Univ, Canc Ctr, Natl Taiwan Univ Hosp, Taipei, Taiwan
[8] Montefiore Albert Einstein Canc Ctr, Dept Oncol, New York, NY USA
[9] Boehringer Ingelheim Taiwan Ltd, Taipei, Taiwan
[10] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[11] Univ Ljubljana, Univ Clin Golnik, Ljubljana, Slovenia
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1532P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
    Liang, Sheng-Kai
    Hsieh, Min-Shu
    Lee, Meng-Rui
    Keng, Li-Ta
    Ko, Jen-Chung
    Shih, Jin-Yuan
    ONCOTARGET, 2017, 8 (52) : 90430 - 90443
  • [42] Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data
    Choi, Juwhan
    Choi, Chang Min
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Ji Young
    Kim, Young-Chul
    Oh, In-Jae
    Jung, Chi Young
    Lee, Sang Hoon
    Yoon, Seong Hoon
    Lee, Sung Yong
    Jang, Tae Won
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2275 - 2282
  • [43] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
    Passaro, A.
    Yang, J. C.
    Ahn, M.
    Dickgreber, N. J.
    Halmos, B.
    Hirsh, V.
    Hochmair, M. J.
    Levy, B. P.
    de Marinis, F.
    Mok, T.
    O'Byrne, K.
    Okamoto, I.
    Schuler, M.
    Sebastian, M.
    Shah, R.
    Tan, E.
    Yamamoto, N.
    Maerten, A.
    Wind, S.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2015, 26 : 77 - 77
  • [44] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC).
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Dickgreber, Nicolas J.
    Halmos, Balazs
    Hirsh, Vera
    Hochmair, Maximilian J.
    Levy, Benjamin Philip
    De Marinis, Filippo
    Mok, Tony
    O'Byrne, Kenneth
    Okamoto, Isamu
    Schuler, Martin H.
    Sebastian, Martin
    Shah, Riyaz N. H.
    Tan, Eng-Huat
    Yamamoto, Nobuyuki
    Marten, Angela
    Massey, Dan
    Wind, Sven
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Impact of afatinib dosing on safety and efficacy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) in a real-world setting
    Halmos, Balazs
    Tan, Eng-Huat
    Soo, Ross
    Cadranel, Jacques
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward
    Melosky, Barbara
    Maerten, Angela
    Carcereny, Enric
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 160 - 161
  • [46] START: Real-world Prospective Study on Sequential Therapy with First-Line Afatinib in Chinese Patients with EGFRm plus Advanced NSCLC
    Zhou, J.
    Xue, Z.
    Li, Q.
    Ling, X.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S632 - S633
  • [47] Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.
    Riely, Gregory J.
    Lovly, Christine Marie
    Messina, Carlo G. M.
    Bienert, Stefanie
    Alexander, Kimberly
    Pao, William
    Baxi, Shrujal
    Doebele, Robert Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Real-world outcomes of second-line osimertinib for advanced NSCLC patients with EGFR mutation in China
    Ji, W.
    Li, X.
    Cang, S.
    Xiang, Y.
    Li, X.
    Zhang, J.
    Tan, J.
    Wang, Q.
    Jiang, D.
    Zhang, H.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1067 - S1067
  • [49] Real World Molecular Testing in Patients with EGFR Mutation-Positive (EGFRM plus ) Locally Advanced or Metastatic NSCLC in Routine Practice in Germany - Interim Results of The Clinical Registry Panorama
    Schuette, Wolfgang
    Schumann, Christian
    Buettner, Reinhard
    Deppertnann, Karl-Matthias
    Reinmuth, Niels
    Thomas, Michael
    Wroblewski, Mark
    Griesinger, Frank
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 118 - 118
  • [50] Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm plus ) NSCLC in LUX-Lung 3, 6 and 7
    Sequist, L. V.
    Wu, Y.
    Schuler, M.
    Kato, T.
    Yang, J. C.
    Tanaka, H.
    Hida, T.
    Lu, S.
    Park, K.
    Paz-Ares, L.
    Laurie, S.
    Bennouna, J.
    Sibilot, D. Moro
    Maerten, A.
    Tang, W.
    Ehrnrooth, E.
    Yamamoto, N.
    Nakagawa, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1572 - S1572
12345